Compare Hinge Health Inc. Class A Common Stock (HNGE) vs VICI Properties Inc (VICI) Price & Performance

Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.

The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.

VICI Properties trades at $22.91, down 0.52% on the day, with a bearish technical signal despite strong fundamentals including a 67.5% net income margin and 9.84% ROE. The stock shows mixed earnings performance with one beat and two misses in recent quarters, while analyst consensus remains strongly bullish with a $28.90 price target representing 26% upside. Recent corporate actions include a $0.46 dividend payment scheduled for October 2026.

The investment case balances attractive valuation metrics (P/E of 8.88, P/B of 0.86) against technical weakness and tenant concentration risks. While cash flow generation remains robust with $2.51B from operations in 2025, investors face headwinds from rising interest rates and potential tenant stress. The 75% buy rating from analysts suggests significant upside potential if execution remains strong.